These observations suggest that a combination of the CD4 and CD57 markers could be sufficient to identify this subset of circulating CD4+CD57+ CTLs, and that the frequency of these cells could therefore represent a novel cellular biomarker of recent, and probably flaring, disease activity in SLE patients. The gene discussed is CD4; the disease is systemic lupus erythematosus.